FDA Class I Recall: Par Sterile Products' Treprostinil Injection Impacted by Particulate Matter
Par Sterile Products LLC has initiated a Class I recall for 466 vials of Treprostinil Injection (Lot#: 57014) due to particulate matter, impacting nationwide U.S. distribution. This high-severity event demands immediate attention from procurement and regulatory teams to assess supply chain integrity and patient safety risks associated with this critical cardiovascular drug. Decision-makers must evaluate current inventory and potential sourcing disruptions.
FDA Initiates Class I Recall for Par Sterile Products' Treprostinil Injection
The U.S. Food and Drug Administration (FDA) has classified a voluntary recall initiated by Par Sterile Products LLC for its Treprostinil Injection, 20 mg/20 mL (1 mg/mL), as Class I, the most severe category. This classification signals a high probability that the use of, or exposure to, the recalled product will cause serious adverse health consequences or death. For procurement directors and regulatory affairs heads, this means immediate action is required to identify and quarantine any affected product within your supply chain. The recall, designated D-0429-2024, was initiated by Par Sterile Products LLC on March 4, 2024, due to the confirmed presence of particulate matter within the vials. Specifically, Lot#: 57014, with an expiration date of April 30, 2024, is impacted. A total of 466 vials of this critical cardiovascular drug, distributed nationwide across the USA, are subject to this recall. The presence of particulate matter in an injectable product like Treprostinil poses significant risks, including emboli, phlebitis, and allergic reactions, which can be life-threatening for patients receiving subcutaneous or intravenous infusions. Business development executives must understand that such a high-severity event can erode trust in product quality and supplier reliability, potentially impacting future market access and partnership opportunities.
Operational Impact and Supply Chain Considerations for Treprostinil
This Class I recall of Treprostinil Injection by Par Sterile Products LLC necessitates an immediate and thorough review of current inventory and sourcing strategies for all companies involved in the distribution or administration of this molecule. Procurement directors must promptly verify if any of the affected Lot#: 57014 vials are present in their stock, ensuring immediate removal from circulation to safeguard patient health and mitigate legal liabilities. The nationwide distribution pattern in the USA indicates a broad impact, requiring comprehensive communication across all relevant stakeholders. For supply chain VPs, the recall of 466 vials of a critical injectable like Treprostinil highlights vulnerabilities in quality control processes for sterile products. While the manufacturing facility for this specific lot is located in Rochester, Michigan, USA, the implications extend to the entire supply chain network. The absence of specific alternative supplier information in the public domain means that organizations relying solely on Par Pharmaceutical for Treprostinil may face immediate supply disruptions. Business development executives should note that consistent product quality is paramount for market stability, and this event underscores the need for robust supplier qualification programs that include rigorous quality audits and contingency planning for single-source dependencies.
Enhanced Regulatory Scrutiny and Future Compliance Outlook for Sterile Injectables
The FDA's Class I classification for Par Sterile Products LLC's Treprostinil Injection recall signals heightened regulatory scrutiny on the manufacturing processes for sterile injectable drugs, particularly concerning particulate matter control. Regulatory affairs heads should anticipate intensified inspections and data requests from the FDA, not only for Par Sterile Products but potentially across the broader industry for similar product categories. This event underscores the FDA's unwavering focus on Good Manufacturing Practices (GMP) compliance, especially for products administered parenterally where patient safety risks from contaminants are severe. While specific details regarding the FDA's next steps for Par Sterile Products LLC are not yet public, such a high-severity recall typically triggers a comprehensive investigation into the root cause of the particulate matter. This could lead to further regulatory actions, including additional recalls, warning letters, or even facility inspections. This incident aligns with a broader trend of regulatory challenges in the sterile manufacturing sector, as evidenced by recent parallel events such as Essential Wellness Pharma's Class II recall for sterility assurance failures. For decision-makers, this means proactively strengthening internal quality systems, investing in advanced particulate detection technologies, and ensuring robust change control processes to prevent similar quality deviations and maintain market access in the highly regulated U.S. pharmaceutical landscape.